20 articles
Duke University study tests whether targeted brain stimulation can reverse age-related cognitive decline and improve working memory.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
A completed Mount Sinai RCT tested whether HBOT can improve brain blood flow and cognition in diabetic elders with mild cognitive impairment.
The EPICURO trial tests MERIVAยฎ turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
Mayo Clinic study reveals how early estrogen treatment affects brain blood flow and cognitive aging in postmenopausal women.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A completed RCT tests whether 6 months of moderate aerobic exercise protects memory and brain structure in older adults at genetic risk for Alzheimer's.
Small study reveals BDNF genetic variant could influence exercise's cognitive and cardiovascular benefits in healthy men.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
TONTT2 tests whether erythropoietin dose and timing can be optimized to best preserve vision after traumatic optic neuropathy.
A completed Canadian platform trial enrolls 354 at-risk adults in a multidomain online brain health program targeting dementia prevention.
A pilot RCT tested whether a smartphone app could improve quality of life and treatment adherence in HIV-positive patients aged 60+.
Brain scans reveal how testosterone suppression in prostate cancer treatment could lead to cognitive decline in aging men.
A completed University of Kansas trial investigates whether creatine monohydrate can support brain energy metabolism in Alzheimer's patients.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
Phase 1b trial tests escalating doses of experimental Alzheimer's treatment BMS-984923 for safety and tolerability in older adults.
Individualized brain training targets specific cognitive weaknesses in adults over 50 with HIV-associated thinking problems.
